TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00991081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling~1. One week prior to the target quit date (TQD)~2. Two weeks post-TQD~3. Four weeks post-TQD

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling~1. One week prior to the target quit date (TQD)~2. Two weeks post-TQD~3. Four weeks post-TQD

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help guide
Description: A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help guide
Description: A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: 8-week course of genetically-tailored pharmacotherapy~* Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~* Participants with the A2 allele (CC) were assigned to receive bupropion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacotherapy
Description: 8-week course of genetically-tailored pharmacotherapy~* Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~* Participants with the A2 allele (CC) were assigned to receive bupropion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic feedback, verbal
Description: During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic feedback, printed
Description: After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
Study: NCT00320242

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1 mo baseline before visual cue
Description: Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
Study: NCT01667445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epimorph
Description: Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal analgesia
Description: Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
Study: NCT01638715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remicade
Description: - Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orencia
Description: - Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: \<60 kg Body weight (BW): 500 mg; \>60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c. application at a dose of 125mg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ro-Actemra
Description: - Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mabthera
Description: - Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.~Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©).
Study: NCT00657800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified inpatient diabetes education program (IDEP)
Description: Assessment of educational needs and coordination of inpatient unit based education program by Certified Diabetes Educator (CDE)
Study: NCT00338962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: paroxetine (40mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: paroxetine (40mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desipramine
Description: 200 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desipramine
Description: 200 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04222777

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cinematographic Recording
Description: A cinematographic recording during the second half of extension of the cervical spine will be made during 16 seconds at two timepoints with an interval of two weeks.
Study: NCT01685229

Intervention type: DEVICE
Intervention: Balloon sinus dilation
Description: Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.

Intervention type: DRUG
Intervention: Medical Management
Description: Subjects who select to continue on medical management rather than have a BSD procedure.
Study: NCT00558844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arikayce™ 560 mg
Description: Arikayce™ at 560 mg~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 560 mg
Description: Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arikayce™ 70 mg
Description: Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arikayce™ 140 mg
Description: Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for 70 mg / 140 mg
Description: Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
Study: NCT01093443

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ovarian stimulation
Description: rFSH with GnRH antagonists

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ovarian stimulation
Description: GnRH antagonist, rFSH, GnRH antagonist
Study: NCT01538641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Gemcitabine, Oxaliplatin
Description: Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.
Study: NCT02287298

Intervention type: PROCEDURE
Intervention: TRIPLE COMBINATION THERAPY
Description: TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY

Intervention type: PROCEDURE
Intervention: TRIPLE COMBINATION THERAPY
Description: TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
Study: NCT03243825

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: combination group
Description: chemotherapy (paclitaxel/cisplatinum) and brachytherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy group
Description: chemotherapy: (paclitaxel/cisplatinum)
Study: NCT00777166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: oxytocin 5 units diluted with normal saline to a total volume of 10 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: oxytocin 10 units diluted with normal saline to at total volume of 10 mL.
Study: NCT00558012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid
Description: Intravenous zoledronic acid 5.0 mg once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous zoledronic acid
Description: Intravenous zoledronic acid 5.0 mg once

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 800 IU/daily
Description: Daily divided dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D 800 IU/daily
Description: Daily divided dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium 1200 mg/daily
Description: supplement plus diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium 1200 mg/daily
Description: supplement plus diet
Study: NCT02380404

Intervention type: PROCEDURE
Intervention: Implants-supported locators placement
Description: Antibiotics will be prescribed 1 day before surgery and continued for 5 days. Three calibrated surgeons will place 4 NN or RN Roxolid tissue level implants. Two implants have to be placed in the ANT region (lateral or canine) and 2 implants in the POST region (as distal as possible). Angulated implant and placement of implant in the tuberosity region can be considered.
Study: NCT03414333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RYGB
Description: RYGB is associated with a increase of circulating GLP-1 (up to ten-fold) especially in response to meal ingestion. This increased availability of GLP1 has been claimed to contribute to restoration of some of the beta-cell function.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: GLP-1 is an hormone secreted by gut in response to nutrients ingestion.
Study: NCT01898169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NJOY King 26 mg nicotine Electronic Nicotine Delivery System
Description: NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.
Study: NCT05761418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: prostaglandin (PG) E2 analog
Study: NCT04870268

Intervention type: PROCEDURE
Intervention: percutaneous drainage
Study: NCT05761418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: prostaglandin (PG) E1 analog
Study: NCT02214940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00305227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactin-V

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02632006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIK-PD-1 cells
Description: DC cell suspension (1×10\*7 DC+ physiological saline~+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10\*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC-PMAT
Description: DC cell suspension (1×10\*7 DC+ physiological saline~+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10\*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT02077686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education - Diabetes and Travel
Description: Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Travel was created. The module covers specific and detailed aspects of the topic travel such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible.
Study: NCT03852589

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC videolaryngoscope
Description: An intubating device that is used for endotracheal intubation. PLMA will inserted by anesthesiologist with C-MAC videolaryngoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blind
Description: PLMA will inserted by anesthesiologist with digital finger.
Study: NCT02601079

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endodrill Biopsy
Description: Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Biopsy forceps
Description: Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
Study: NCT02915159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01945879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparine
Description: al patients received additional low molecular heparin, if the safety cohort of three patients received at least 4 weeks of combined treatment without severe side effects, recruitment were continued until a minimum of 15 patients completed at least 3 months of treatment.
Study: NCT04407676

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Summary PIS and Online Video Modules
Description: Complex trial information presented in alternative and more accessible formats

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Summary PIS and Online Video Modules
Description: Complex trial information presented in alternative and more accessible formats
Study: NCT03363607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital indirect bonding
Description: Indirect bonding of orthodontic attachments using digital 3D printed transfer tray

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional indirect bonding
Description: Indirect bonding of orthodontic attachments using thermoformed transfer tray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoral scanning
Description: Intraoral Scanning of the bonded brackets

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoral scanning
Description: Intraoral Scanning of the bonded brackets

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superimposition and evaluation
Description: superimposition of the brackets' positions before and after bonding and evaluation of the transfer accuracy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superimposition and evaluation
Description: superimposition of the brackets' positions before and after bonding and evaluation of the transfer accuracy
Study: NCT03756948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Treatment of Coagulation Disorders Using Standard Coagulation Tests and Blood Components

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
Description: Thromboelastometry-Guided Treatment of Coagulation Disorders Using Synthetic Factor Concentrates
Study: NCT00113295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continued Paroxetine CR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continued Paroxetine CR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT02418793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-5014
Description: Long Acting Factor VIIa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-5014
Description: Long Acting Factor VIIa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-5014
Description: Long Acting Factor VIIa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-5014
Description: Long Acting Factor VIIa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-5014
Description: Long Acting Factor VIIa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-5014
Description: Long Acting Factor VIIa
Study: NCT04654715

Intervention type: PROCEDURE
Intervention: Gracilis flap interposition for rectouretral fistula management
Description: Gracilis flap interposition is a surgery for rectouretral fistula
Study: NCT04013295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prize-linked savings
Description: Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money.
Study: NCT03614403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
Study: NCT04531423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI + golimumab
Description: Golimumab will be administered at the dose of 50mg every month during the acute phase.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SSRI + placebo
Description: placebo
Study: NCT03310242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sunlight Exposure
Description: * Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks~* Completing a Sun Diary after sunlight exposure

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation
Description: - Supplementation of vitamin D3 500 IU/day for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: - Intake of placebo for 8 weeks
Study: NCT01967771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG will be supplied as 50 mg tablet to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBZ
Description: CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally
Study: NCT01953042

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: 4 educational sessions covering information on diagnosis, treatment, available resources and self care for OCD and OCD Spectrum Disorders
Study: NCT02244047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium breve

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Bifidobacterium breve)